marijuana stock news


Tetra Bio-Pharma Inc.(TSXV:TBP) (“Tetra” or “TBP”) announces a correction to its press release entitled “TETRA BIO-PHARMA ANNOUNCES $10.0 MILLION BOUGHT DEAL OFFERING” issued today (the “Initial Press Release“).

The Initial Press Release incorrectly stated that the Offering, as defined therein, will be completed by way of a short form prospectus to be filed in all of the provinces and territories of Canada other than Quebec. However the Offering will be conducted in all the provinces of Canada, including Quebec, but excluding the territories of Canada. This correction does not change any other information reported in the Initial Press Release.

About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit:

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the success of this product  or any other product, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.


SOURCE Tetra Bio-Pharma Inc.

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 |
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Tilray Brands Inc. (TLRY) Expands Beer Portfolio and Launches Good Supply Light Beer

Tilray Brands Expands Beer Portfolio and Launches Good Supply Light Beer Tilray…

Indiva Limited (NDVAF) Announces Pre-Roll Partnership with the Supreme Cannabis Company, Inc. (SPRWF)

Indiva Announces Pre-Roll Partnership with the Supreme Cannabis Company, Inc. Indiva Limited…

AYR Wellness Inc. (AYRWF) Reaches Agreement on GSD NJ and Sira Naturals Earn-Out Amendments

AYR Wellness Reaches Agreement on GSD NJ and Sira Naturals Earn-Out Amendments…

$TRTC Derek Peterson, Provides Update and Outlook in a New Audio Interview

Terra Tech Corp. CEO, Derek Peterson, Provides Update and Outlook in a…